



## **New In-Cell-Art Website with Online Ordering System to Meet Increasing Demands of ICAfectin® Transfection Reagents**

**Nantes – France, 7th of March, 2013** – In-Cell-Art, a biotechnology company specializing in nanocarrier technologies called Nanotaxi® for macromolecules delivery (DNA, RNA, Protein), announces the opening of new In-Cell-Art website with intuitive and flexible online ordering system for novel DNA and siRNA in-vitro transfection reagents called ICAfectin®.

This online ordering has been established in response to increasing requests of ICAfectin® from various countries outside France (USA, Canada Germany, India, Israel and more). Five new types of transfection reagents (ICAfectin®293, 448, 451 and 452) have been also added to ICAfectin® product line. The information of ICAfectin® products are found online at;

DNA transfection reagents

<http://www.incellart.com/en/icafectin/dna-transfection.html>

siRNA transfection reagents

<http://www.incellart.com/en/icafectin/sirna-transfection.html>

Selection of publications

<http://www.incellart.com/en/icafectin/publications-2.html>

Ordering

<http://www.incellart.com/en/icafectin/ordering-en.html>

Bruno Pitard, co-founder of In-Cell-Art, said “The strategic focus is in vivo macromolecules delivery for Vaccine & Antibodies Discovery but as there are also increasing demands of in vitro transfection reagents from all over the world, In-Cell-Art decided to establish the online ordering system. This solution will lead to faster response and delivery, cheaper price and higher customer satisfactions”.

### **About In-Cell-Art**

In-Cell-Art (ICA), which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. In-Cell-Art offers a range of reagents and biotechnology development services:

## **1. ICANTibodies™**

In the absence of recombinant antigen, ICANTibodies™ allows, from an in silico DNA antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed nuclear, cytoplasmic, secreted or membrane proteins. ICANTibodies™ has allowed, in less than 2 years, the production of more than 250 different functional antibodies. In-Cell-Art has worked with a number of pharmaceutical firms (Sanofi, GlaxoSmithKline, Geneuro etc.) and public research institutions and universities (Institut Cochin, Cancer Research UK, Institute of Neurology UK etc).

## **2. ICA Nanotaxi®**

- DNA Vaccine

ICA614 Nanotaxi®, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 Nanotaxi® represents a crucial step in DNA vaccine development, and is currently being tested by major vaccine companies (Sanofi-Pasteur, Merial etc.).

- mRNA Vaccine

Some other ICA Nanotaxi® are also being assessed in \$33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced Research Projects Agency (DARPA). The consortium would validate the new application of ICA Nanotaxi® for mRNA-based vaccines for infectious diseases in collaboration with CureVac and Sanofi-Pasteur.

## **3. ICAFectin® transfection reagents**

ICAFectin® transfection reagents are innovative breakthrough synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections as demonstrated by their increasing use in numerous studies published in high impact factor journals including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS Pathogen, Human Gene Therapy and more.

In-Cell-Art is a privately held company, which was founded in 2005. It is a member of the Atlanpole Biotherapies high-tech cluster of biotechnology companies in western France.

For further information please contact;

In-Cell-Art

Sohei Fukuyama, Business Development and Alliance Management

Tel: 33 (0)2 40 71 67 17

E-mail: [sohei.fukuyama@incellart.com](mailto:sohei.fukuyama@incellart.com)

Website : <http://www.incellart.com>